NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $15.52 -0.13 (-0.83%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$15.60 +0.08 (+0.52%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$15.18▼$15.9550-Day Range$14.96▼$18.7552-Week Range$14.19▼$42.50Volume4.93 million shsAverage Volume3.37 million shsMarket Capitalization$4.39 billionP/E RatioN/ADividend YieldN/APrice Target$26.11Consensus RatingHold Company Overview Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology. Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis. In addition to clinical testing for patient care, the company offers translational science and clinical trial support services to biopharmaceutical partners, including biomarker discovery, assay development and companion diagnostic collaborations to facilitate drug development programs. The company primarily serves healthcare providers, cancer centers and biopharma customers in the United States and through international collaborations. Its offerings are used across the oncology care continuum—from initial profiling to inform therapy selection through longitudinal monitoring and research applications—positioning the business at the intersection of clinical diagnostics and precision oncology research. Caris emphasizes the integration of multi‑omic data and computational analysis to generate clinically actionable insights, and it engages with clinicians, researchers and industry partners to expand the use of molecular profiling in personalized cancer care. Detailed information about its leadership and corporate history is available through the company’s public filings and corporate disclosures. AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreCAI MarketRank™: Caris Life Sciences scored higher than 96% of companies evaluated by MarketBeat, and ranked 3rd out of 63 stocks in the services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingCaris Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on no strong buy ratings, 6 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialCaris Life Sciences has a consensus price target of $26.11, representing about 68.2% upside from its current price of $15.52.Amount of Analyst CoverageCaris Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth450.00% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 450.00% in the coming year, from $0.06 to $0.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caris Life Sciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Caris Life Sciences is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 7.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.30% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 3.39, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently decreased by 17.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.88 News SentimentCaris Life Sciences has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Services companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search Interest5 people have searched for CAI on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows1 people have added Caris Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Caris Life Sciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,491,538.00 in company stock, which represents 0.0340% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,491,538.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences: Disrupting Cancer Screening And Therapy SelectionJuly 21, 2026 | seekingalpha.comCaris Life Sciences (CAI) Stock Looks Undervalued On A 47% SlumpJuly 18, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.July 26 at 1:00 AM | Banyan Hill Publishing (Ad)Caris Life Sciences (CAI) Sets August Results Date, Is The Stock Undervalued?July 18, 2026 | finance.yahoo.comCaris Life Sciences (CAI) Launches In House PTEN Test After FDA Prostate Cancer ApprovalJuly 17, 2026 | finance.yahoo.comCaris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026July 16, 2026 | prnewswire.comCaris Life Sciences, Inc. (CAI) Receives a Buy from Bank of America SecuritiesJuly 14, 2026 | theglobeandmail.comCaris Life Sciences (NASDAQ:CAI) Director Acquires $990,080.00 in StockJuly 14, 2026 | insidertrades.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 at the beginning of the year. Since then, CAI stock has decreased by 42.5% and is now trading at $15.52. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) announced its quarterly earnings results on Thursday, February, 26th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.27. Caris Life Sciences's revenue was up 125.4% compared to the same quarter last year. Read the conference call transcript. Is Caris Life Sciences doing a stock buyback? Caris Life Sciences' board initiated a share buyback program on Monday, June 8th 2026, which permits the company to buy back $100,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 2.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its shares are undervalued. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an initial public offering on Wednesday, June 18th 2025. The company issued 23,529,412 shares at a price of $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Caris Life Sciences' top institutional investors include Handelsbanken Fonder AB (0.01%). Insiders that own company stock include Jon Halbert, Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today7/26/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorServices Industry Services – Health Sub-IndustryHealthcare Current SymbolNASDAQ:CAI CIK2019410 WebN/A Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$26.11 High Price Target$32.00 Low Price Target$21.00 Potential Upside/Downside+68.2%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($7.61) Trailing P/E RatioN/A Forward P/E Ratio258.67 P/E GrowthN/ANet Income-$68.09 million Net Margins3.75% Pretax Margin3.73% Return on Equity98.28% Return on Assets48.87% Debt Debt-to-Equity Ratio0.64 Current Ratio7.05 Quick Ratio6.52 Sales & Book Value Annual Sales$812.03 million Price / Sales5.40 Cash Flow$1.59 per share Price / Cash Flow9.74 Book Value$2.05 per share Price / Book7.57Miscellaneous Outstanding Shares282,680,000Free Float141,341,000Market Cap$4.39 billion OptionableN/A BetaN/A Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CAI) was last updated on 7/26/2026 by MarketBeat.com Staff. From Our PartnersThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
